Medikamentöse Therapie von Knochenstoffwechselstörungen bei CKD-MBD („chronic kidney disease – mineral bone disorder“) unter besonderer Berücksichtigung antiresorptiver Wirkstoffe

Abstract

Disturbances in bone and mineral turnover are common complications in patients with impaired renal function. Besides an increased risk for cardiovascular events they promote skeletal events, such as bone pain and fractures. Evidence for the antifracture efficacy of antiresorptive and osteoanabolic treatment strategies has only been demonstrated for patients with osteoporosis. The use of osteotropic drugs in patients with impaired renal function requires large randomized placebo-controlled trials.

Denosumab Use in Chronic Kidney Disease Associated Osteoporosis: A Narrative Review

“…1 Bone and mineral turnover disturbances are common complications in patients with impaired kidney function, advanced CKD, or on maintenance dialysis. 2,3 Because of low bone mineral density (BMD) and poor bone quality, patients with chronic kidney disease-mineral and bone disorders (CKD-MBD) are at a higher risk of bone fractures and associated morbidity and mortality. 1,4,5 The term CKD-MBD was coined by the Kidney Disease Improving Global Outcomes Foundation (KDIGO) in replacement of the term renal osteodystrophy.…”